InvestorsHub Logo
Followers 22
Posts 4084
Boards Moderated 0
Alias Born 04/29/2016

Re: trding post# 9827

Saturday, 01/28/2017 2:05:22 PM

Saturday, January 28, 2017 2:05:22 PM

Post# of 233441
Trding..it is absolutely correct. They hired this firm for more exposure as we are so far under the radar pre Croi. See below:

NEW YORK, NY / ACCESSWIRE / December 22, 2016 / CytoDyn Inc. (the "Company") (CYDY), a biotechnology company focused on the development of new antibody therapies for combating human immunodeficiency virus (HIV) infection and other diseases, announces that it has engaged the expertise of NetworkNewsWire ("NNW"), a multifaceted financial news and publishing company that delivers a new generation of social communication solutions, news aggregation and syndication, and enhanced news release services. NNW's strategies help public and private organizations find their voice and build market visibility via social media and a rapidly expanding distribution network of well over 5,000 key syndication outlets.

"Maintaining strong communication with CytoDyn shareholders is highly important as we pursue regulatory approval of PRO 140, our leading monoclonal antibody for HIV infection," says Nader Pourhassan, Ph.D., president and chief executive officer of CytoDyn. "As we focus on our ongoing Phase 3 clinical trial with PRO 140, NNW will work behind the scenes and use its vast network to keep existing and potential investors up-to-date on our progress."

As part of the Client-Partner relationship with CytoDyn, NNW will leverage its investor-based Brand Network of partners, various newsletters, social media channels, blogs, and other outreach tools to generate greater brand awareness for the Company.

"Though tremendously invaluable, communication strategies are an often overlooked aspect of business for many biotech and biopharma companies," states Sherri Franklin, director of Content Marketing for NNW. "CytoDyn, however, is taking a proactive approach in making sure the investment community is aware of its progress. We look forward to working with this exciting company as it addresses a significant global concern and advances its clinical development of monoclonal antibodies for treatment of HIV infection."

About CytoDyn

CytoDyn is a biotechnology company focused on the clinical development and potential commercialization of humanized
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent CYDY News